OBJECTIVE: Depression is associated with more severe cognitive deficits in many neurological disorders, though the investigation of this relationship in Huntington disease (HD) has been limited. This study examined the relationship between depressive symptom severity and measures of executive functioning, learning/memory, and attention in prodromal HD. METHOD: Participants (814 prodromal HD, 230 gene-negative) completed a neuropsychological test battery and the Beck Depression Inventory-II (BDI-II). Based on the BDI-II, there were 637 participants with minimal depression, 89 with mild depression, 61 with moderate depression, and 27 with severe depression in the prodromal HD group. RESULTS: ANCOVA (controlling for age, sex, and education) revealed that performance on SDMT, Trails B, Hopkins Verbal Learning Test--Revised (HVLT-R) Immediate Recall, and Stroop interference was significantly different between the BDI-II severity groups, with the moderate and severe groups performing worse than the minimal and mild groups. There were no significant differences between the BDI-II severity groups for Trails A or HVLT-R Delayed Recall. Linear regression revealed that both gene status and depression severity were significant predictors of performance on all cognitive tests examined, with contributions of BDI-II and gene status comparable for Trails A, SDMT, and Stroop interference. Gene status had a higher contribution for HVLT-R Immediate and Delayed Recall and Trails B. CONCLUSIONS: Our results suggest that depressive symptom severity is related to poorer cognitive performance in individuals with prodromal HD. Though there are currently no approved therapies for cognitive impairment in HD, our findings suggest that depression may be a treatable contributor to cognitive impairment in this population.
OBJECTIVE: Depression is associated with more severe cognitive deficits in many neurological disorders, though the investigation of this relationship in Huntington disease (HD) has been limited. This study examined the relationship between depressive symptom severity and measures of executive functioning, learning/memory, and attention in prodromal HD. METHOD: Participants (814 prodromal HD, 230 gene-negative) completed a neuropsychological test battery and the Beck Depression Inventory-II (BDI-II). Based on the BDI-II, there were 637 participants with minimal depression, 89 with mild depression, 61 with moderate depression, and 27 with severe depression in the prodromal HD group. RESULTS: ANCOVA (controlling for age, sex, and education) revealed that performance on SDMT, Trails B, Hopkins Verbal Learning Test--Revised (HVLT-R) Immediate Recall, and Stroop interference was significantly different between the BDI-II severity groups, with the moderate and severe groups performing worse than the minimal and mild groups. There were no significant differences between the BDI-II severity groups for Trails A or HVLT-R Delayed Recall. Linear regression revealed that both gene status and depression severity were significant predictors of performance on all cognitive tests examined, with contributions of BDI-II and gene status comparable for Trails A, SDMT, and Stroop interference. Gene status had a higher contribution for HVLT-R Immediate and Delayed Recall and Trails B. CONCLUSIONS: Our results suggest that depressive symptom severity is related to poorer cognitive performance in individuals with prodromal HD. Though there are currently no approved therapies for cognitive impairment in HD, our findings suggest that depression may be a treatable contributor to cognitive impairment in this population.
Authors: Laura K Sheridan; Hiram E Fitzgerald; Kenneth M Adams; Joel T Nigg; Michelle M Martel; Leon I Puttler; Maria M Wong; Robert A Zucker Journal: Arch Clin Neuropsychol Date: 2005-08-31 Impact factor: 2.813
Authors: Kevin Duff; Jane S Paulsen; Leigh J Beglinger; Douglas R Langbehn; Julie C Stout Journal: Biol Psychiatry Date: 2007-05-03 Impact factor: 13.382
Authors: Eric A Epping; James A Mills; Leigh J Beglinger; Jess G Fiedorowicz; David Craufurd; Megan M Smith; Mark Groves; Kelly R Bijanki; Nancy Downing; Janet K Williams; Jeffrey D Long; Jane S Paulsen Journal: J Psychiatr Res Date: 2013-06-19 Impact factor: 4.791
Authors: Aaron Bonner-Jackson; Jeffrey D Long; Holly Westervelt; Geoffrey Tremont; Elizabeth Aylward; Jane S Paulsen Journal: J Int Neuropsychol Soc Date: 2013-05-23 Impact factor: 2.892
Authors: Mandi Musso; Holly James Westervelt; Jeffrey D Long; Erin Morgan; Steven Paul Woods; Megan M Smith; Wenjing Lu; Jane S Paulsen Journal: J Int Neuropsychol Soc Date: 2015-01 Impact factor: 2.892
Authors: Fay E Bolsover; Elaine Murphy; Lisa Cipolotti; David J Werring; Robin H Lachmann Journal: J Inherit Metab Dis Date: 2013-08-16 Impact factor: 4.982
Authors: Tua Vinther-Jensen; Ida U Larsen; Lena E Hjermind; Esben Budtz-Jørgensen; Troels T Nielsen; Anne Nørremølle; Jørgen E Nielsen; Asmus Vogel Journal: Orphanet J Rare Dis Date: 2014-07-17 Impact factor: 4.123
Authors: Christopher A Ross; Ralf Reilmann; Francisco Cardoso; Elizabeth A McCusker; Claudia M Testa; Julie C Stout; Blair R Leavitt; Zhong Pei; Bernhard Landwehrmeyer; Asuncion Martinez; Jamie Levey; Teresa Srajer; Jee Bang; Sarah J Tabrizi Journal: Mov Disord Clin Pract Date: 2019-08-23